| 19 |
安睿，申新，李爽，等. 血小板与肠道屏障功能的研究进展[J/CD]. 中华危重症医学杂志（电子版），2020，13(2): 145-148.
|
| 20 |
杨华，韩晓蘋，李宝静，等. 35例朗格罕细胞组织细胞增生症的临床病理影像特点、预后及治疗方法分析[J]. 中国实验血液学杂志，2014，22(4): 1109-1114.
|
| 21 |
苗苗，吴涛，陆小亚，等. 朗格汉斯细胞组织细胞增生症一例临床病例分析[J]. 中国医师进修杂志，2016，39(12): 1121-1122.
|
| 22 |
Wang X, Yang S, Tu P, et al. A case of Langerhans cell histiocytosis in an adult with initial symptoms confined to the skin[J]. Int J Dermatol, 2010, 49 (3): 337-339.
|
| 23 |
吴润晖，赵新民. 郎格罕细胞组织细胞增生症研究进展及CD1a检测的应用[J]. 中国小儿血液，2000，5(4): 188-191.
|
| 24 |
Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society[J]. Pediatr Dermatol, 2008, 25 (3): 291-295.
|
| 25 |
Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis[J]. Blood, 2016, 128 (20): 2462-2465.
|
| 26 |
王宏胜，李军，马伴吟，等. 改良DAL-HX 83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察[J]. 中国小儿血液与肿瘤杂志，2007，12(2): 60-63.
|
| 27 |
刘子勤，刘嵘，胡涛，等. 婴幼儿朗格汉斯细胞组织细胞增生症临床特点和生存分析[J]. 中国医刊，2011，46(5): 46-51.
|
| 28 |
Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group[J]. Klin Padiatr, 2000, 212 (4): 139-144.
|
| 29 |
Alston RD, Tatevossian RG, McNally RJ, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998[J]. Pediatr Blood Cancer, 2007, 48 (5): 555-560.
|
| 30 |
Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning[J]. Bone Marrow Transplant, 2005, 36 (3): 215-225.
|
| 31 |
Lai CC, Huang WC, Cheng SN. Successful treatment of refractory Langerhans cell histiocytosis by allogeneic peripheral blood stem cell transplantation[J]. Pediatr Transplant, 2008, 12 (1): 99-104.
|
| 32 |
刘子勤，王天有. 朗格罕斯细胞组织细胞增多症发病机制及治疗[J]. 临床儿科杂志，2009，27(8): 709-713.
|
| 33 |
张鼎，赵斌. 朗格汉斯组织细胞增生症的诊治进展[J]. 医学信息，2019，32(19): 35-38.
|
| 34 |
李君惠，刘嵘，胡涛，等. 克拉屈滨治疗难治复发朗格汉斯细胞组织细胞增生症1例并文献复习[J]. 中国医刊，2014，49(8): 45-48.
|
| 35 |
胡涛，刘嵘，李君惠，等. 克拉屈滨治疗儿童难治性高危朗格汉斯细胞组织细胞增生症：13例报告并文献复习[J]. 中华血液学杂志，2014，35(11): 985-988.
|
| 36 |
张奉齐，王季石，吴莉. 朗格汉斯细胞组织细胞增生症1例报道并文献复习[J]. 现代医药卫生，2017，33(1): 153-154.
|
| 1 |
许霞，刘卫平，杨群培，等. Langerhans细胞组织细胞增生症258例临床病理特征和免疫表型分析[J]. 中华病理学杂志，2012，41(2): 91-96.
|
| 2 |
Lichtenstein L. Histocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schüller-Christian disease as related manifestations of a single nosologic entity[J]. AMA Arch Pathol, 1953, 56 (1): 84-102.
|
| 3 |
赵云，赵红，孙春华，等. 眼睑朗格汉斯细胞组织细胞增生症一例[J]. 中华眼视光学与视觉科学杂志，2016，18(10): 631，635.
|
| 4 |
Allen CE, Ladisch S, McClain KL. How I treat Lang-erhans cell histiocytosis[J]. Blood, 2015, 126 (1): 26-35.
|
| 5 |
EI Demellawy D, Young JL, de Nanassy J, et al. Lan-gerhans cell histiocytosis: a comprehensive review[J]. Pathology, 2015, 47 (4): 294-301.
|
| 6 |
黄伟华，王春燕，罗群，等. 36例肺朗格汉斯细胞组织细胞增生症临床分析[J]. 结核与肺部疾病杂志，2021，2(2): 131-138.
|
| 7 |
Jeziorski E, Senechal B, Molina TJ, et al. Herpes-virus infection in patients with Langerhans cell histiocytosis: a case-controlled sero-epidemiological study, and in situ analysis[J]. PLoS One, 2008, 3 (9): e3262.
|
| 8 |
Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis[J]. Proc Am Thorac Soc, 2006, 3 (4): 299-306.
|
| 9 |
葛荣，殷宪刚，刘创峰，等. 成人朗格汉斯组织细胞增生症的临床病理学分析[J]. 中华医学杂志，2012，92(42): 2995-2997.
|
| 10 |
Varqa E, Korom I, Polyánka H, et al. BRAFV600E mutation in cutaneous lesions of patients with adult Langerhans cell histiocytosis[J]. J Eur Acad Dermatol Venereol, 2015, 29 (6): 1205-1211.
|
| 11 |
Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis[J]. Pediatr Int, 2014, 56 (4): 451-461.
|
| 12 |
唐雪，郭霞，孙林雍，等. 儿童朗格汉斯细胞组织细胞增生症的BRAF-V600E基因突变及临床意义[J]. 中国当代儿科杂志，2018，20(4): 290-294.
|
| 13 |
Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy[J]. J Clin Oncol, 2016, 34 (25): 3023-3030.
|
| 14 |
Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups[J]. J Exp Med, 2014, 211 (4): 669-683.
|
| 15 |
Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation[J]. Blood, 2013, 121 (9): 1495-1500.
|
| 16 |
张永久，陈琳，郭红，等. BRAFV600E基因突变与甲状腺乳头状癌相关性研究[J]. 西北国防医学杂志，2015，36(4): 211-213.
|
| 17 |
马雁南，涂彩霞，王傲雪. 朗格汉斯细胞组织细胞增生症治疗进展[J]. 中国皮肤性病学杂志，2018，32(2): 218-222.
|
| 18 |
郭智，何学鹏，陈惠仁，等. 朗格汉斯细胞组织细胞增生症3例临床分析[J]. 实用癌症杂志，2010，25(4): 402-404.
|